Sunday, November 18, 2007

Dolly creator Prof Ian Wilmut shuns cloning

I'm sure that you all have heard about this already but it's such good news that I couldn't help but comment. Thank you, Lord that this man has turned back from this heinous endeavor to pursue research that will ultimately be less damaging to humanity.

Prof Ian Wilmut's decision to turn his back on "therapeutic cloning", just days after US researchers announced a breakthrough in the cloning of primates, will send shockwaves through the scientific establishment.

He and his team made headlines around the world in 1997 when they unveiled Dolly, born July of the year before.

But now he has decided not to pursue a licence to clone human embryos, which he was awarded just two years ago, as part of a drive to find new treatments for the devastating degenerative condition, Motor Neuron disease.

Prof Wilmut, who works at Edinburgh University, believes a rival method pioneered in Japan has better potential for making human embryonic cells which can be used to grow a patient's own cells and tissues for a vast range of treatments, from treating strokes to heart attacks and Parkinson's, and will be less controversial than the Dolly method, known as "nuclear transfer."

His announcement could mark the beginning of the end for therapeutic cloning, on which tens of millions of pounds have been spent worldwide over the past decade. "I decided a few weeks ago not to pursue nuclear transfer," Prof Wilmut said.

Most of his motivation is practical but he admits the Japanese approach is also "easier to accept socially."

His inspiration comes from the research by Prof Shinya Yamanaka at Kyoto University, which suggests a way to create human embryo stem cells without the need for human eggs, which are in extremely short supply, and without the need to create and destroy human cloned embryos, which is bitterly opposed by the pro life movement.
It is to his credit that he has walked away from his research and didn't cling to it out of pride as some would have done.